QurAlis taking three ALS programs toward clinic with $42M series A

A broadened investor syndicate will help QurAlis advance programs targeting disease subpopulations

After launching with a modest seed round in 2018, neurology company QurAlis is driving toward the clinic with a $42 million series A round to fund development of three therapies to treat amyotrophic lateral sclerosis and genetically-driven frontotemporal dementia.

Polaris Partners, Mission BioCapital, INKEF Capital and the Dementia Discovery Fund led the round. Also participating were Droia Ventures, Mitsui Global Investment, Dolby Family Ventures, Amgen Ventures, MP Healthcare Venture Management and Sanford

Read the full 710 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE